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REVIEW
Aims: To discuss the current methodological and conceptual difficulties inherent in
characterizing the emotional manifestations of neurodegenerative disease through critically
reviewing depression as a manifestation of idiopathic Parkinson’s disease (PD).
Methods: Selective literature review of the neurobiological, psychological, and physical basis
of depressive symptoms in PD from 1993–2003, with reference to key earlier articles.
Conclusions: There are difficulties in defining the syndromes of PD itself as well as depression
in PD. The use of more conceptually reductionistic definitions of emotion and behavior in
comprehensive longitudinal studies of the natural history of PD is recommended.
Keywords: Parkinson’s disease, depression, nosology
My propositions serve as elucidations in the following way: anyone who understands
me eventually recognizes them as nonsensical, when he has used them – as steps – to
climb up beyond them. (He must, so to speak, throw away the ladder after he has
climbed up it.) WITTGENSTEIN 1974, p 89
Introduction
We wish to explore some of the epistemological and methodological issues regarding
the phenomenology, nosology, and ultimately, the investigation of neuropsychiatric
disorders. In particular, we will focus on the constraints of applying standardized
criteria for depression (WHO 1992; APA 2000), developed for the relatively
neurologically healthy, to emotional disorders such as depression in neurodegenerative
disease. As a prototypical neuropsychiatric disorder, Parkinson’s disease affects
cognition, emotion, autonomic, and motor aspects of the nervous system. In this
critical review, we seek to focus on the phenomenon of depression in Parkinson’s
disease, with a view to better appreciating the difficulties that face those seeking to
investigate the nature of emotional disorders in neurodegenerative disease. We
acknowledge that other syndromes within Parkinson’s disease, such as psychosis,
may also lend themselves to such exploration, as may other neuropsychiatric disorders
such as Alzheimer’s disease and vascular dementias. For brevity, and because the
arguments may be similarly applied to a lesser or greater degree in these other
conditions, we have focused on depression in Parkinson’s disease.
Difficulties in characterizing the emotional
manifestations of Parkinson’s disease
Parkinson’s disease is an age-related neurodegenerative disorder characterized by
the physical manifestations of resting tremor, rigidity, bradykinesia, and postural
instability (Gelb et al 1999; Schrag et al 2002). Despite Parkinson’s original
observation of preservation of the mental faculties, it is now well recognized that
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there are cognitive and emotional manifestations of the
disease (Waters 1998). Depression has been described as
the major psychological complication, with a prevalence of
2%–70% in those suffering from PD (Hoogendijk et al 1998;
Becker et al 2002). Indeed, when matched for comparable
degrees of physical disability with disorders such as
osteoarthritis and diabetes, a higher prevalence of depressive
disorders were found in the PD group in a large Danish
cohort (Murray 1996; Nilsson et al 2001).
However, the characterization of the emotional and
cognitive consequences of cerebral neurodegenerative
disease remains fraught with misconceptions and
uncertainties. Heretofore, the delineation of the psychiatric
consequences of neurodegenerative disease has involved
surveying patients suffering from neurodegenerative disease
with standardized psychiatric diagnostic instruments to
characterize psychiatric syndromes described as depression,
mania, anxiety, and psychosis. Such an approach has
limitations, particularly in Parkinson’s disease (PD), due to
diagnostic uncertainties in differential diagnosis of
idiopathic PD (the major parkinsonian syndrome) from other
etiologically distinct parkinsonian syndromes;
manifestations of PD which may present as behavioral
mimics or phenocopies of depression (Berrios et al 1995)
such as apathy; issues of circular/self-referential
classification through application of diagnostic criteria for
depression in otherwise healthy persons to diagnose
depression in PD; and the ongoing debate as to whether a
distinct depression in idiopathic PD exists. Indeed, the
conceptual challenge of depression in PD has recently been
discussed from a semantic and epistemological viewpoint,
with reference to the pathophysiology (Leentjens and Verhey
2002). Our focus is somewhat different, and seeks to
specifically explore the conceptual and methodological
difficulties of defining depression in PD. In particular, we
seek to explore how the application of a predetermined




Parkinsonism itself is a protean entity and aside from
idiopathic Parkinson’s disease (PD) may result from
Parkinson’s-plus syndromes such as corticobasal ganglionic
degeneration, multiple systems atrophy, progressive
supranuclear palsy, or Lewy-Body dementia (Poewe and
Wenning 2002). Furthermore, Parkinsonism may be
secondary to toxic insults, infections, cervical/cerebral
trauma (such as a component of dementia pugilistica), or
cerebrovascular disease. Finally, other unrelated movement
disorders may masquerade as Parkinson’s disease, such as
Huntington’s disease, Wilson’s disease, or familial
olivopontocerebellar atrophy.
In addition, a specific etiopathogenesis has not been
identified with putative causative factors including genetic
factors, toxins, oxidative stress, mitochondrial dysfunction,
glutamergic excitotoxicity, glial, neurotrophic, and apoptosis
being postulated (Olanow and Tatton 1999).
The relative paucity of in vivo, clinically valid, available,
and specific biomarkers for PD renders differential diagnosis
difficult, as does the absence of specific clinical features
that may differentiate idiopathic PD from other Parkinsonian
syndromes (Gelb et al 1999). Idiopathic Parkinson’s disease
may therefore be misdiagnosed at rates approaching
20%–30% (Poewe and Wenning 2002); and at autopsy,
characteristic neuropathological changes are only confirmed
in 75% of cases (Gelb et al 1999). Functional neuroimaging
techniques such as assessment of striatonigral dopaminergic
activity using I
123 Beta-CIT or I
123 FP-CIT single photon
emission computerized tomography (SPECT), a ligand for
the dopamine transporter in the caudate and putamen, have
utility in confirming the diagnosis of Parkinson’s disease
(Duchesne et al 2002; Piccini and Whone 2004). The ratio
of caudate to putamen activity shows a 50% reduction of
I
123 Beta-CIT binding in the putamen by disease presentation
in PD, with a relatively poorly differentiating relative
reduction of binding in the caudate for atypical Parkinsonian
syndromes (Brucke et al 1997; Gerschlager et al 2002;
Piccini and Whone 2004). Positron emission tomography
(PET) has relatively less clinical utility due to the
requirement of a cyclotron for generation of the
radioisotopes used. Of the PET modalities, 
18F-dopa PET
has the most utility, demonstrating loss of up to 50% of
normal 18F-dopa ( a marker of accumulation and metabolism
of levodopa) uptake in caudal putamen; however, again
differentiation from progressive supranuclear palsy, multiple
systems atrophy, or corticobasal degeneration remains
problematic (Antinoni et al 1997; Ghaemi et al 2002; Piccini
and Whone 2004).
Leentjens and Verhey (2002), assert that Parkinson’s
disease is a distinct disease entity in contradistinction to
psychiatric syndromal diagnosis such as depression. In
contrast, we assert that in clinical practice Parkinson’s
disease is a syndrome rather than a disease, given that weNeuropsychiatric Disease and Treatment 2005:1(2) 137
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are unable to ascertain neurobiological data to confirm the
diagnosis. This is supported by the relative lack of valid,
specific biomarkers such as functional brain neuroimaging
and data on misdiagnosis cited above. Furthermore,
idiopathic PD is ipso facto of unknown etiopathogenesis,
and clinical features do not necessarily correlate with
classical neuropathology. We therefore argue that PD and
depression both represent syndromal constructions.
However, the core syndrome of idiopathic PD is associated
with characteristic neuropathological changes postmortem,
and there has been speculation on what neurophysiological,
neurochemical, and neuroanatomical alterations may serve
as the substrate for possible disturbances of cognition and
emotion in PD. Here we find ourselves dashed upon the
shores of psychiatric syndromal diagnosis, as depression
and other psychiatric complications of PD have been
heretofore defined using standardized criteria for psychiatric
diagnosis designed for neurologically intact and otherwise
healthy persons.
Self-referential or circular
definitions of depression in PD
In current psychiatric nosology, depression has been defined
by operationalized diagnostic criteria formulated by the
American Psychiatric Association (DSM-IV) (APA 2000)
and the World Health Organization (ICD-10) (WHO 1992)
classification of mental disorders. Thus, the diagnosis of
major depressive disorder is predicated on the presence of
five or more symptoms: low mood, anhedonia, sleep
disturbances, weight loss, psychomotor agitation, fatigue,
guilt, poor concentration, and suicidal ideation present for
more than two weeks (DSM-IV) (APA 2000). This
syndromal diagnosis has little reference to putative
etiopathogenesis or clinical course apart from a duration
specific qualifying period and mandatory exclusion factors
(Leentjens and Verhey 2002). The assessment of depression
in clinical research has been made by means of structured
clinical interviews and/or assessment via depression rating
scales based on these criteria.
These extant criteria and methods for assessing
depression have been applied for the diagnosis of
“depression” in PD, generating an inherent circularity. That
is, one can only characterize depression in PD within the
confines of the construct of DSM-IV/ICD-10 major
depression, thereby precluding us from identifying possibly
unique features of the emotional manifestations of PD.
Indeed, this type of circularity is not new in the
neuropsychiatric literature and has been remarked upon with
the definition of vascular cognitive impairment upon a
paradigmatic definition derived from Alzheimer’s disease
(Looi and Sachdev 1999).
Incidence of parkinsonism in
persons with depression
Several studies have identified that depression often predates
a diagnosis of PD, providing increasing evidence for a
common etiology of the two disorders. There have been
several studies that have shown depression to be a risk factor
for the development of PD (Nilsson et al 2001; Schuurman
et al 2002), and several retrospective case control studies
showing that PD is preceded by a prodromal phase,
characterized by an increased incidence of mood disorders
(Gonera et al 1997; Shiba et al 2000). However, the most
substantial evidence has come from an epidemiological
study, where the lifetime incidence of depressive disorder
was calculated for patients, from a general practice based
register, until their diagnosis of PD and compared with that
of a matched control population from the same register
(Leentjens et al 2003). This study found that at the time of
their diagnosis of PD, 9.2% of the patients had a history of
depression, compared with 4% of the control population.
In addition, Nilsson et al (2002), via analysis of a Danish
register, found a significant increased risk for hospitalization
because of depression in patients with PD compared with
subjects with osteoarthritis or diabetes mellitus, providing
further support for the hypothesis that depression in patients
with PD is a consequence of a shared pathophysiological
basis.




The known neuropathology of PD comprises age-related
degeneration of dopaminergic neurons in the substantia nigra
pars compacta associated with intracytoplasmic aggregates
of alpha-synuclein known as Lewy bodies (Olanow and
Tatton 1999). These neurodegenerative changes and Lewy
bodies are also found in the locus coeruleus, nucleus basalis
of Meynert, hypothalamus, cerebral cortex, brainstem motor
nuclei, and autonomic nervous system (Berg et al 1999;
Olanow and Tatton 1999). As would be expected from such
widespread neuropathology, the PD process may potentiallyNeuropsychiatric Disease and Treatment 2005:1(2) 138
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impact upon a number of structures, circuits, and
neurotransmitter function, yielding widespread effects on
cognition and emotion.
The role of neurochemical changes in PD in causing
depressive symptomatology remains largely speculative. It
is important to emphasize that the majority of data pertain
to neurochemical and neuropathological changes in
Parkinson’s disease per se, rather than in depressed
Parkinson’s disease patients. We have summarized the
relevant findings in Tables 1 and 2, with Table 1 describing
neurochemical changes and Table 2 describing neuro-
pathological changes (Mann and Yates 1983; Cash et al
1984; Mayeux et al 1984, 1986; Kostic et al 1987; Turkka
et al 1987; Chan-Palay and Asan 1989; Pachetti et al 1990;
Paulus and Jellinger 1991; Kuhn et al 1996; Bertrand et al
1997; Engelborgh et al 2003). There are conflicting data on
the serotonin metabolite 5-hydroxy-indoleacetic acid, with
some studies showing decreased levels in depressed PD
patients (Mayeux et al 1984, 1986; Kostic et al 1987) and
others equally showing no significant differences (Kuhn et
al 1996). The evidence for the effects of dopamine and
depression has been similarly lacking (Kuhn et al 1996). At
best the role of noradrenaline is speculative at present.
Putative neuroanatomical substrates have been based on
neuropsychological evidence of frontal system dysfunction
(Starkstein and Mayberg 1992; Murray 1996; Schrag et al
2001; Slaughter et al 2001), frontomesial pathology
(Starkstein and Petracca 1998), and frontal system
hypometabolism on SPECT and PET (Becker et al 2002).
Frontal-executive dysfunction is the most common
Table 1 Neurochemical changes in Parkinson’s disease (PD)
Results
Authors Sample characteristics Dopamine Noradrenaline Serotonin
Engelborgh et al 2003 Comparison of CSF biogenic  Dopamine metabolite No statistically significant 5HT was significantly higher
amines in PD vs aged (DOPAC) significantly change in CSF NA levels and 5HIAA was significantly
matched controls lower in PD compared between PD and controls lower in PD group with
PD(n) = 24 with control 5HIAA/5HT ratio lower in PD
Controls (n) = 30 group reflecting decreased
5HT catabolism
Kuhn et al 1996 Comparison of de novo No significant difference No significant difference No significant difference of
depressed (PDd) and between CSF levels of between CSF levels of 5HIAA between the PDd group
non-depressed (PDn) dopamine and its noradrenaline and its and the PD group
Parkinson’s disease patients metabolites between PDd metabolites between the
PDd (n) = 14 and the PD groups PDd group and PD group
PDn (n) = 12
Pacchetti et al 1990  Comparison between No significant difference in
depressed and 5HIAA CSF between PDd
non-depressed PD patients and PD
PD (n) = 52, of which 20 are
de novo patients
Kostic et al 1987  Significantly lower 5H1AA
levels in PD and more so in
PDd compared with controls
Turkka et al 1987 Levels of CSF NA was
not significantly different
between PD and aged
matched controls
Mayeux et al 1986 Comparison between Levels of CSF 5HIAA was
depressed and non-depressed lowest in PDd than in PD
PD patients. 10-day
dopamine-free period
PD (n) = 49
Mayeux et al 1984 Data found that CSF 5HIAA
content of PDd was lower
than PD
Abbreviations: CSF, cerebrospinal fluid; NA noradrenaline.Neuropsychiatric Disease and Treatment 2005:1(2) 139
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neuropsychological deficit demonstrated in PD (Levy et al
2002; Cummings and Mega 2003) and its occurrence is
predictive of dementia (Mahieux et al 1998; Levy et al 2002).
The deficits described comprise problems with memory
retrieval, word-list generation, organization of complex
visual copying, and shifting of cognitive set (Mahieux et al
1998; Cummings and Mega 2003). Dysfunction in these
systems could result in symptomatology consistent with
depression such as executive dysfunction and impaired
concentration. Furthermore, there is emerging evidence that
non-verbal emotional information processing is impaired
early in PD (Dujardin et al 2004) and that this may contribute
Table 2 Neuropathological changes in Parkinson’s disease (PD)
Results
Authors Design Substantia nigra Locus coeruleus (LC) Dorsal raphe nucleus (DRN)
Mann and Yates 1983 PD (n) = 8. PD cases not LC degeneration in PD
recruited for depression. cases. Greater adrenergic
cell loss in those with
dementia relating to the 
disease process.
Cash et al 1984 PD (n) = 20. Thirteen of Increased adrenergic
the PD patients had receptors in the prefrontal
dementia. Patients not cortex of parkinsonian
recruited for depression. patients. Greater increases
Unable to establish in alpha1 adrenergic
diagnosis of depression receptors were noted in
in any of the cases. PD patients with dementia.
Suggestion that the increase
in adrenergic receptors is
a compensatory mechanism
in relation to a drenergic
cell loss.
Chan-Palay et al 1989 PD (n) = 7. Post-mortem LC neuronal degeneration and
study of heterogenous PD cell loss. Decreased LC length.
group. Chronic elderly Greater degeneration of LC 
PD patients, not specifically was noted in the PDd.
recruited for depression.
Five of the PD patients had
rapidly progressive
dementia MMSE 0–5, two
of which were atypically
depressed and were not
L-dopa responsive.
Paulus and Jellinger 1991 Post-mortem studies of PD patients significant cell Reduced cell count in the Reduced cell count in PD
elderly PD patients some loss compared with LC of PD compared with compared with controls.
with comorbid dementia, controls. controls. PD (n) = 23
depression, and psychosis. PD (n) = 37 Controls (n) = 6
Diagnosis of depression and Controls (n) = 12 Density of neurons in the DRN
psychosis was retrospective No difference in LC count in PD depressed was lower.
based on clinical notes. and density in between PD (n) = 9
depressed and PDd (n) = 12
non-depressed PD.
Bertrand et al 1997 Post-mortem study of 21 Significant loss of adrenergic
PD cases. One case was neurons in LC. LC neuronal
known to have severe loss increases with disease
dementia. Cases did not duration. Significantly
differentiate between decreased LC neurons in the
depressed and patient with severe dementia.
non-depressed patients.
Abbreviations: MMSE, Mini-Mental State Examination.Neuropsychiatric Disease and Treatment 2005:1(2) 140
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to a presentation consistent with depression. The role of the
basal limbic system and associated brainstem nuclei
dysfunction in contributing to depressive symptoms remains
more speculative at this stage, but potentially could be
responsible for deficits in mood, behavior, and sleep (Berg
et al 1999; Becker and Berg 2001).
Disruptions of circuit connectivity in the brain have been
postulated as a possible mechanism for post-stroke
depression, in the absence of clear evidence of
neurotransmitter dysfunction (Herrmann et al 1995). The
pathways implicated traverse the basal ganglia and involve
the intricate white matter loops interconnecting the structures
known as the frontosubcortical circuits, with resultant
changes in cognition and emotion, and have been implicated
in major depression in otherwise healthy persons (Austin et
al 2001). In addition, dysfunction in autonomic circuitry,
as evinced by orthostasis and postural instability and its
association with depression, has been demonstrated (Berrios
et al 1995; Schrag et al 2001). Furthermore, disruption of
these frontosubcortical circuits results in frontal-executive
dysfunction, such as is found in vascular cognitive
impairment (Looi and Sachdev 2000) and which has been
noted in uncomplicated depression (Austin et al 2001). It is
possible, albeit speculative, that remote upstream or
downstream effects described as diaschisis may result from
neurodegeneration in the basal ganglia and associated
circuitry in PD, and thereby, may contribute to local or
distant changes in motor, cognitive, and affective functions
resembling depression. This would explain the occurrence
of frontal-executive dysfunction, associated depressive
symptomatology, and anxiety symptoms in PD. It therefore
follows that the core neurobiological changes of PD may
result in a neurobehavioral syndrome resembling depression
(Cummings and Mega 2003).
Manifestations of PD as behavioral
mimics or phenocopies of
depression
Behavioral manifestations of PD such as agitation, anxiety,
anhedonia, apathy, and psychosis may individually or
synergistically serve as phenocopies of depression (Berrios
et al 1995). Agitation, apathy, and anxiety have been
identified as being highly prevalent in epidemiological
surveys of persons with PD (Aarsland et al 1999). These
behavioral changes may be misidentified as depression due
to their resemblance to clinical manifestations of DSM-IV
major depression. Apathy refers to reduced interest and
participation in normal purposeful behavior, lack of
initiative, and indifference with affective blunting (Pluck
and Brown 2002). Apathy has now been recognized as a
prominent and important manifestation of the emotional
consequences of PD, having been demonstrated to be more
prevalent in those with PD compared with equally disabled
patients with osteoarthritis in the absence of differences in
personality traits or cognition (Pluck and Brown 2002). Up
to 40% of patients with PD may experience significant
anxiety, a higher than expected level for age-matched
controls and that this may be clustered into panic disorder,
phobias, and generalized anxiety disorder (Starkstein et al
1993; Walsh and Bennett 2001). In particular, generalized
anxiety may closely resemble agitated depression via
restlessness (which can be interpreted as psychomotor
agitation), rumination on trivial concerns, and seeking of
reassurance. Furthermore, panic attacks may also mimic
agitated depression. Anhedonia itself has been identified as
a prominent neuropsychiatric symptom of PD, in the absence
of association with mood (Isella et al 2003) and representing
a deficit in novelty seeking behavior. Thus, anhedonia may
represent part of the core neuropsychiatric disturbance in
PD, secondary to deficits in the dopamine reward circuits,
and may masquerade as depression (Menza and Mark 1994).
In addition, psychosis may also occur frequently in PD and
may therefore mimic a psychotic depression.
The diagnostic confusion is further exacerbated by
cognitive and physical manifestations of PD which also
resemble features of depression, such as impaired
concentration, cognitive/psychomotor slowing, brady-
kinesia, reduced libido, fatigue, and sleep disturbance
(Happe et al 2001; Leentjens and Verhey 2002; Pluck and
Brown 2002; Schuurman et al 2002; Lieberman 2003). There
may be somatic preoccupations with genuine physical
complications such as dizziness, tinnitus, epigastric pain,
headaches, bladder, and bowel disturbances (Leentjens and
Verhey 2002).
The idea that the physical and behavioral manifestations
of PD may resemble depression and is a neurobiological
manifestation of the disorder is not new (Cummings and
Mega 2003). Indeed, Berrios and colleagues (1995)
concluded that anxiety and depression in a proportion of
PD patients was a behavioral phenocopy induced by
autonomic dysfunction (Lerner and Whitehouse 2002).
However, we would broaden this concept to include the
range of cognitive, emotional, and physical symptoms of
PD that may mimic the depressive syndrome.Neuropsychiatric Disease and Treatment 2005:1(2) 141
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A specific syndrome of low mood
in PD?
It would seem self-evident that depression could be
conceptualized as an understandable reaction to the suffering
caused by PD. However, such an approach has been already
been identified as being overly simplistic and is contradicted
by the lack of association between disease factors and
progression with the degree of severity of depression
(Starkstein et al 1989; Troster et al 1995; Lerner and
Whitehouse 2002).
Much has been written about a distinct syndrome of low
mood or depression characteristic to PD, which is somehow
distinct from the conventional definition of “idiopathic” (for
want of a better term) depression (Cummings and
Masterman 1999; Stocchi and Brusa 2000; Myslobodsky et
al 2001; Slaughter et al 2001; Yamamoto 2001; Cummings
and Mega 2003). This distinction has proved difficult to
demonstrate, and we suggest that this is due to a priori
application of conventional criteria for depression to the
depressive syndrome of PD, thereby constraining the data
obtained as opposed to a more descriptive approach such as
using an inventory of psychiatric syndromes. Some authors
have identified that depressive cognitions are less prevalent
in PD than in idiopathic depression (Yamamoto 2001).
Others have identified a greater preponderance of somatic
symptoms (sleep disturbance, decreased appetite, and
anhedonia), dysphoria, suicidal ideation, and a qualitative
difference in the nature of the sadness (Slaughter et al 2001).
A majority have stated that anxiety symptoms are prominent,
there is a lack of mood-congruent psychosis and there are
low suicide rates despite a high frequency of suicidal ideation
(Cummings and Masterman 1999; Stocchi and Brusa 2000;
Myslobodsky et al 2001; Slaughter et al 2001; Yamamoto
2001). Is anxiety being misdiagnosed as depression? Does
the lack of suicidal behavior reflect a syndrome of apathy?
What are the comorbidity rates of apathy, anxiety, and
agitation in PD? Despite these questions, others maintain
that there are no characteristic differences between
depression in PD and idiopathic depression in older adults
(Erdal 2001).
Climbing up the ladder
We would therefore conclude that Parkinson’s disease is, in
a clinical setting, a syndrome of considerable heterogeneity.
Extant psychiatric diagnostic criteria for depression so
closely approximate the clinical cognitive, emotional, and
physical manifestations of the PD syndrome so as to render
the syndromes indistinguishable in part or whole. How are
clinicians, especially in primary care, to struggle with the
vicissitudes of diagnosis of depression in PD? The putative
neurobiological basis of idiopathic PD may be expected to
result in emotional consequences consistent with major
depression as currently defined. Phenomenological and
clinical understanding of the cognitive and emotional
consequences of PD, such as depressive symptoms, can best
be advanced by careful integrated longitudinal study of the
physical, cognitive, and emotional consequences of PD
syndromes. Such longitudinal studies should use more
conceptually reductionistic diagnostic criteria for emotional
consequences such as apathy, specific anxiety syndromes,
anhedonia, insomnia, and psychosis as well as the broader
construct of “depression” to better characterize these core
phenomena without being constrained to an a priori
conceptualization of depression. However, it is not entirely
pragmatic to eschew the guideposts of description of
emotional distress provided by conventional psychiatric
nosology, as these provide at least a means of discourse
regarding emotional distress and because research to date
has utilized such diagnostic criteria to describe these
phenomena. Practically, therefore, we suggest inclusion of
descriptors of more discrete cognitive and emotional
phenomena as well as including classifications according
to standardized criteria for depression in longitudinal studies
of the natural evolution of Parkinson’s disease, a process
which has been possible in the analogous investigation of
the emotional and cognitive aspects of cerebrovascular
disease (Sachdev et al 2004).
We would propose such longitudinal studies of
depression in PD should:
1. Examine patients with early-stage PD;
2. Comprehensively characterize their physical, cognitive,
and emotional function using measures of motor
dysfunction, autonomic function, disability, anxiety,
apathy, anhedonia, and cognitive function;
3. In parallel, collect information on depression according
DSM-IV/ICD-10 psychiatric classifications;
4. Examine cognitive and emotional processing of anxious
and depressive thinking in PD;
5. Utilize structural and functional brain neuroimaging to
assist in identifying the neuroanatomical and
neurochemical bases of depressive symptoms in PD.
In this way, we may free ourselves from the conceptual
oubliette of a predetermined concept of depressive
symptomatology in describing the cognitive and emotional
manifestations of Parkinson’s disease.Neuropsychiatric Disease and Treatment 2005:1(2) 142
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